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beneficial to human health and the approach to be used in
reviewing the science.
The final regulation explains in considerable detail the
changes made and the underlying rationale for each.2
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In Reply Drs Mayne and Balentine disagree with our state-
ment about the inclusion of purified additives such as inulin
and cellulosic fibers on the fiber line of the revised Nutrition
Facts label.We believe that inclusion of these isolated or syn-
thetic constituents on the label togetherwithnaturally occur-
ring fibers fromfruits, vegetables, andwholegrainscanbemis-
leading to consumers andmisused by foodmanufacturers to
portray otherwise unhealthy products as healthy.
We understand that the FDA has revised the definition
of dietary fiber as part of the updated label regulation to in-
clude isolated or synthetic nondigestible carbohydrates dem-
onstrated to have a single physiological benefit such as
cholesterol-lowering effects or “improved laxation.” Thus
“cellulosic fiber,”with the nutritional value of cardboard, can
be included on the fiber line if it is shown to improve laxa-
tion.This canbemisleading toconsumersbecauseamajor rea-
son for promoting foods that are high in fiber is that they con-
sistently are associated with a lower risk of diabetes and
cardiovascular disease.1 These relationships are probably
driven in part because the fiber component is a marker for
myriadminerals, vitamins, andphytonutrients that travelwith
the fiber, and there is no evidence that the addition of cellu-
loseor inulinwill have the samebenefit. Inotherwords, a food
made with whole grains is not the same as a food made with
refined grains and added cellulose. The FDA’s new definition
of fiber does notmake this distinction andwill therefore con-
tribute to confusion, especially when gauging the quality of
carbohydrate foods using the ratio of total carbohydrates to
fiber.This ratiohasbeen recommendedby theAmericanHeart
Association as a guide for identifying whole grains.2 The cur-
rent dietary guidelines for Americans recommend consum-
ing a combinationof fruits, vegetables, andwhole grains to in-
crease fiber intake,3 but there is no evidence that increasing
fiber (as defined by the FDA) will provide the same benefits
as consuming these fiber-rich whole foods.
We believe that the Nutrition Facts label would better
guide consumer choices if it only included on the fiber line
fiber that is intrinsically part of food ingredients and did not
include isolated or synthetic constituents. There may be
some exceptions to this such as bran, which could be consid-
ered a food ingredient because it comes with the naturally
accompanying nutrients. This is not to say that pure cellulose
or other synthetic, isolated nondigestible carbohydrates
should not be allowed in foods, but rather that they should
not be included on the fiber line. If such ingredients are to be
included on the Nutrition Facts label, they should be on a
separate line for “isolated or synthetic fiber.”
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Euthanasia or Assisted Suicide in PatientsWith
Psychiatric Illness
To the Editor Drs Olié and Courtet1 commented on the report
by Dr Kim and colleagues2 on euthanasia or assisted suicide
(EAS) of psychiatric patients in the Netherlands, highlighting
the challenges surrounding the legalization of EAS in pa-
tients with a psychiatric illness.
Olié and Courtet1 mentioned the option of palliative care
for terminally ill patients as a possible alternative to EAS.
We believe that the achievements of contemporary palliative
care indicate relevance beyond the context of terminal
somatic illness for the group of people suffering from severe
persistent mental illness. For these patients, we advocate a
shift toward patient-oriented palliative care, centered on the
ethical principle of patient self-determination. Given its
focus on empowering people with mental illness, the
recovery movement is already heading in this direction.3
However, some people with severe persistent mental illness
may have a long history of failed functional recovery. Their
suffering may be unbearable and their therapeutic options
exhausted. In such specific cases, a reorientation of care
goals toward symptom relief as the main focus of care—
possibly without modifying the course of the disease—may
be a legitimate option.
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The authors1 also mentioned the possibility of EAS evalu-
ations in the interests of suicide prevention. Although suicide
prevention has a long history in psychiatry, there are poten-
tial risks in focusing mainly or exclusively on impeding sui-
cide without taking into account the risks of overly aggres-
sive care or even coercion. The severe adverse effects and
interactions of polypharmacy, as well as the patient’s (and
physician’s) possible sense of failure, may result in an even
poorer quality of life for the patient.4 We agree with Dr Yager5
that hyperinterventionism (especially against the patient’s
wishes) and treatment excesses are not supportable; and that
even patients with partially impaired decision-making capac-
ity retain some capacity to make prudent decisions regarding
their long-term desires.
We are aware of the controversy surrounding futility and
palliative care for patients with severe persistent mental
illness.4,5However, apalliativeapproach inpsychiatrydoesnot
meangivinguponapatient but rather involves redefining the
goals of care. This entails accepting the reality thatmental ill-
ness can be fatal. With improvements in the quality of care,
there might be fewer requests for EAS.
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In Reply We agree with Ms Hodel and Dr Trachsel when they
conclude, “With improvements in the quality of care, there
might be fewer requests for EAS.” According to the article by
Dr Kim and colleagues,1 most patients receiving EAS for psy-
chiatric conditionsdidnot receive accurate treatment for their
mental state and level of suffering that couldhave led toavoid-
ingEAS.DrTrachsel and colleagues2 suggestedpalliative care
in psychiatry for severe persistent mental illness, including
long-termresidential carepatientswith severe chronic schizo-
phrenia and insufficient quality of life; those with therapy-
refractory depression; and persons with severe, long-
standing, therapy-refractory anorexia nervosa. Most EAS
psychiatricpatients in the seriesbyKimandcolleaguesdidnot
meet these criteria.
A common definition of palliative interventions includes
that they help to stabilize or improve quality of life without
necessarily modifying disease progression in the long term.
Using this definition, several clinical approaches in psychia-
try can be considered palliative because they aim at reducing
symptoms and suffering from mental illness rather than
seeking to achieve disease remission. But quality of life is
often improved and suicide risk is reduced when palliative
support takes place in addition to curative or disorder-
specific treatments. Under no circumstances should the term
“palliative” be used to justify negligent or careless treatment
of patients.
We do not agree with the assessment that suicide pre-
vention consists of overly aggressive care. Promising results
have already been reported for the use of ultra–low-dose
buprenorphine to reduce psychological pain and suicidal
ideation with a favorable safety profile.3 Beyond pharmaco-
logical treatments that may be not well tolerated by some
patients, specific psychotherapies have also begun to be
developed to reduce death and promote recovery of psychi-
atric patients. For example, a short-term program of accep-
tance and commitment therapy has suggested efficacy in
suicide prevention with a high acceptability rate.4
In addition, empowering people with mental illness
applies to suicide prevention. The Suicide Attempt Survi-
vors Task Force of the National Action Alliance for Suicide
Prevention5 proposes to involve individuals who have
attempted suicide in active prevention efforts so that per-
sons currently contemplating suicide “may gain hope and a
sense of empowerment through connection to … experience
of those who have ‘been there.’”
Another issue ismental competence of personswith psy-
chiatric illness requesting EAS. Psychiatric disease increases
the risk of impaired decision-making capacity. Capacity-
specificabilitiesconsistofabilities tounderstandrelevant facts,
apply those facts to oneself, reason and weigh the facts, and
evidence a stable choice. Among the 66 psychiatric patients
receivingEAS in theNetherlands,only5had informationabout
these4componentsmentioned in theirmedical records.6Most
often, capacity-specific discussion consistedof only global as-
sertionofapatient’s capacitywithoutdetails.Moreexplicitdis-
cussion of how such patients are able to meet the various ca-
pacity-specific criteria, despite their symptoms, should be
expected. As guarantors of health, not of death, physicians
should trust further advances in psychiatry to promote new
alternatives to EAS.
Emilie Olié, MD, PhD
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CORRECTION
Incorrect Section Headings in Figures: In the US Preventive Services Task
Force Evidence Report entitled “Primary Care Interventions to Support Breast-
feeding: Updated Evidence Report and Systematic Review for the US Preventive
Services Task Force,” published in the October 25, 2016, issue of JAMA,1 section
headings were incorrect in figures. In Figures 3, 4, and 5, the heading for the top
section should have read, “Timing of intervention: combination of prenatal,
perinatal, or postnatal,” and the heading for the bottom section should have
read, “Timing of intervention: only prenatal, perinatal, or postnatal.” This article
has been corrected online.
1. Patnode CD, Henninger ML, Senger CA, Perdue LA, Whitlock EP. Primary care
interventions to support breastfeeding: updated evidence report and
systematic review for the US Preventive Services Task Force. JAMA. 2016;316
(16):1694-1705.
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